Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Table 1 Variables used to construct clinical patient scenarios in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors

Variable	Range of values
Anatomic site	Pancreatic neuroendocrine tumors
Line of treatment	Observation; first-line treatment; second-line treatment; third-line treatment
Patient’s primary problem	Uncontrolled secretory symptoms; uncontrolled tumor-related symptoms; rapid radiographic progression; nonrapid radiographic progression; no symptoms and no radiographic progression; no symptoms
Postmarker and postscan testing status	No progression from prior marker and scan; progression after prior marker and scan
Frequency of testing a patient with markers and scans	Every 3 mo; every 6 mo; every 9 mo; every 12 mo
Cytoreductive surgery	Optimal cytoreductive surgery; suboptimal cytoreductive surgery; not a candidate for surgery
Systemic therapy	Somatostatin analog; everolimus; sunitinib; cytotoxic chemotherapy; interferon-α; temozolomide-containing regimen; streptozotocin-containing regimen
Response to lower octreotide LAR dose	Previously responded to a lower dose or frequency; previously did not respond to a lower dose or frequency
Octreotide LAR frequency	Every 2 wk; every 3 wk; every 4 wk
Octreotide LAR dosing	30 mg; 40 mg; 60 mg; 90 mg; 120 mg